CD14 and COVID-19: In addition, several novel biomarkers for differentiating the disease severity of COVID-19 were also studied, for example, serum-neuron-specific enolase (NSE—a pulmonary injury biomarker in lung cancer) [101], and presepsin (a soluble CD14; a proinflammatory activator of immune cells) [102].